Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 253 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: levodopa Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sustained Release Oral Formulation for Treatment of Parkinson's Disease

NCT05471609
View directory record Official record
Conditions
Healthy Volunteers
Interventions
levodopa/carbidopa oral formulation A, levodopa/carbidopa oral formulation B
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 25, 2026, 1:51 AM EDT
Terminated Phase 2Phase 3 Interventional

Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

NCT05116813
View directory record Official record
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Interventions
Dipraglurant
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
30 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Augusta, Georgia • Kansas City, Kansas • New Brunswick, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 25, 2026, 1:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of a Pre-Workout Dietary Supplement

NCT02952014
View directory record Official record
Conditions
Dietary Modification
Interventions
C4 Extreme, C4 Extreme (without Advantra Z, Placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 25, 2026, 1:51 AM EDT
Completed Phase 1 Interventional

Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

NCT05094050
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 25, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

NCT02799381
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump, Percutaneous endoscopic gastrostomy tube, Jejunal extension tube
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Port Charlotte, Florida • Round Rock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 25, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491932
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders, Anti-Dyskinesia Agents
Interventions
AFQ056
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Englewood, Colorado • Kansas City, Kansas • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 25, 2026, 1:51 AM EDT
Terminated Phase 1 Interventional

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

NCT02589340
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesias, Movement Disorders
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 25, 2026, 1:51 AM EDT
Recruiting Phase 1 Interventional

Diagnosis of Pheochromocytoma

NCT00004847
View directory record Official record
Conditions
Pheochromocytoma, Endocrine Disease, Endocrine Diseases
Interventions
([18F]-DOPA), ([18F]-6F-DA)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 120 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2048
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 1:51 AM EDT
Completed Early Phase 1 Interventional

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

NCT03599726
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 25, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

NCT00001849
View directory record Official record
Conditions
Cushing Syndrome, Endocrine Disease
Interventions
Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG
Drug · Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 25, 2026, 1:51 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

NCT03887884
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVT-301, Sinemet
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Long Beach, California • Hallandale, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 25, 2026, 1:51 AM EDT
Completed Phase 3 Interventional

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

NCT04750226
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 25, 2026, 1:51 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

NCT01536015
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
30 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
26
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 25, 2026, 1:51 AM EDT
Completed Phase 4 Interventional Results available

DTA (Dopaminergic Therapy for Anhedonia) Study

NCT04723147
View directory record Official record
Conditions
Depression, Anhedonia
Interventions
Carbidopa Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 25, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

NCT00253084
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX054 200 mg, CD-LD IR, IPX054 Placebo, CD-LD IR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 25, 2026, 1:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Action Regulation Behavioral

NCT06489483
View directory record Official record
Conditions
Parkinson Disease
Interventions
Action Regulation Movement Task
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 25, 2026, 1:51 AM EDT
Active, not recruiting No phase listed Observational

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

NCT06107426
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
27
States / cities
Birmingham, Alabama • Sun City, Arizona • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 25, 2026, 1:51 AM EDT
Recruiting No phase listed Observational

Udall Project 2 Aim 2A&C

NCT05656586
View directory record Official record
Conditions
Parkinson Disease
Interventions
observational-- no intervention
Other
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 25, 2026, 1:51 AM EDT
Completed Not applicable Interventional Results available

Computational Modeling of 60 Hz Subthalamic Nucleus Deep Brain Stimulation for Gait Disorder in Parkinson's Disease

NCT04184791
View directory record Official record
Conditions
Parkinson Disease
Interventions
Deep Brain Stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
21 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 25, 2026, 1:51 AM EDT
Completed No phase listed Observational

Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia

NCT00912977
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 25, 2026, 1:51 AM EDT
Not yet recruiting Phase 4 Interventional

Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics

NCT07793461
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Levodopa (L-dopa)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 1:51 AM EDT
Completed Phase 1Phase 2 Interventional

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

NCT05083260
View directory record Official record
Conditions
Parkinson Disease
Interventions
NE3107, placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
16
States / cities
Englewood, Colorado • Boca Raton, Florida • Hallandale, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 25, 2026, 1:51 AM EDT
Recruiting Not applicable Interventional

Motor Network Physiology

NCT04957095
View directory record Official record
Conditions
Parkinson Disease, Essential Tremor
Interventions
Apomorphine Injectable Solution, Subcortical Stimulation
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 1:51 AM EDT
Withdrawn Phase 4 Interventional

Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation

NCT02346630
View directory record Official record
Conditions
Stroke
Interventions
Placebo, Levodopa / Carbidopa, Armeo
Drug · Device
Lead sponsor
Ross D. Zafonte, MD
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Oct 25, 2026, 1:51 AM EDT